Inventiva (IVA) EBIT Margin (2020 - 2021)
Inventiva (IVA) recorded quarterly EBIT Margin of 21021.54% in Q2 2021, down 56.47% quarter-over-quarter from 13435.14% in Q1 2021, and down 904857.0% on a YoY basis from N/an in Q2 2020.
Inventiva (IVA) EBIT Margin (2020 - 2021) Analysis & Trends
Inventiva's EBIT Margin history runs 2 years deep, the most recent figure standing at 21021.54% for Q2 2021.
- In Q2 2021, EBIT Margin fell 904857.0% year-over-year to 21021.54%; the TTM figure through Jun 2021 stood at 21339.07% (changed N/A YoY), while the FY2025 annual figure was 3145.51%, down 208486.0% from the prior year.
- EBIT Margin was 21021.54% for Q2 2021 at Inventiva, down from 13435.14% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 7821.84% in Q1 2020 to a low of 21021.54% in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Inventiva | 8.93 Mn | -259.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -21,021.54% |
| Mar 31, 2021 | -13,435.14% |
| Jun 30, 2020 | -11,972.97% |
| Mar 31, 2020 | -7,821.84% |